Feb 24, 2026 07:00AM
Jan 13, 2026 06:34AM
Jan 12, 2026 07:08AM
Jan 12, 2026 07:00AM
Dec 12, 2025 06:21AM
Dec 8, 2025 06:46AM
Dec 4, 2025 10:02AM AxoGen, Inc. (AXGN) PT Raised to $36 at Raymond James
Dec 4, 2025 07:27AM
Dec 3, 2025 08:01PM
Dec 3, 2025 08:01PM
Oct 30, 2025 05:37AM
Oct 29, 2025 01:26PM
Oct 29, 2025 07:00AM
Oct 1, 2025 01:20PM Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
Aug 25, 2025 11:01AM
Aug 25, 2025 06:40AM
Aug 25, 2025 06:40AM
Aug 11, 2025 07:05AM
Aug 5, 2025 07:00AM
Jul 29, 2025 01:02PM
May 8, 2025 07:05AM Axogen, Inc. Reports 2025 First Quarter Financial Results
Feb 25, 2025 04:39PM
Feb 25, 2025 07:00AM
Nov 7, 2024 07:00AM
Sep 6, 2024 07:00AM
Sep 6, 2024 07:00AM
Aug 13, 2024 04:18PM
Aug 8, 2024 07:00AM Axogen, Inc. Reports Second Quarter 2024 Financial Results
Jun 24, 2024 07:00AM
May 28, 2024 04:30PM
May 16, 2024 07:02AM
May 16, 2024 07:00AM
May 2, 2024 07:00AM
Apr 29, 2024 04:50PM
Mar 5, 2024 07:00AM Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Nov 7, 2023 07:00AM
Aug 7, 2023 04:01PM
May 9, 2023 07:00AM
May 4, 2022 04:01PM
May 4, 2022 04:01PM
May 4, 2022 04:01PM
Sep 1, 2021 07:07AM AxoGen (AXGN) RECON Study Supporting BLA Completes Subject Follow-up
Sep 1, 2021 07:00AM
Sep 1, 2021 07:00AM
Aug 4, 2021 04:01PM
Aug 4, 2021 04:01PM
Jul 22, 2020 07:20AM
Jul 22, 2020 07:00AM
Jul 22, 2020 07:00AM Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects
May 6, 2020 04:01PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All